[192 Pages Report] Immunofluorescence assay is a powerful technique used to analyze the distribution of glycans, proteins, and small biological and non-biological molecules (cells and tissues) using antibodies conjugated with a fluorescent dye, known as fluorophore, which can be visualized using a fluorescence microscope or imaging systems. The immunofluorescence assay market is expected to reach USD 2.01 Billion by 2023 from USD 1.43 Billion in 2017, at a CAGR of 5.8%. The increasing prevalence of chronic diseases, increasing R&D spending, and increasing healthcare spending are the major factors driving the growth of the market. The base year considered for the study is 2017 and the forecast period includes 2018 to 2023.

Objectives of the Study

To define, describe, and forecast the global immunofluorescence assay market on the basis of product, type, disease, end user, and region

To provide detailed information regarding major factors influencing the growth market (drivers, restraints, opportunities, and challenges)

To strategically analyze micromarkets with respect to the individual growth trends, future prospects, and contributions to the overall market

To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World, along with major countries in these regions

To profile the key players and comprehensively analyze their market shares and core competencies in the market

To track and analyze competitive developments such as product launches, expansions, agreements, partnerships, acquisitions and research and development activities in the global market

Research Methodology

Top-down and bottom-up approaches were used to validate the size of the global market and estimate the size of other dependent submarkets. Various secondary sources such as directories, industry journals, databases such as D&B Hoovers, Bloomberg Business, and Factiva, and annual reports of the companies have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of this immunofluorescence assay industry. The breakdown of profiles of primaries is shown in the figure below:

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the global immunofluorescence assay market are Thermo Fisher (US), Inova Diagnostics (US), Bio-Rad (US), Abcam (UK), PerkinELmer (US), Merck Millipore (US), Cell Signaling Technology (US), MEDIPAN GMBH (Germany), Sino Biological (China), Danaher (US), and Vector Laboratories (US).

Target Audience:

Manufacturers of immunofluorescence kits, reagents, and equipment

Suppliers and distributors of immunofluorescence kits, reagents, and equipment

Research institutes

Academic institutions

Contract research organizations

Health insurance payers

Market research and consulting firms

Venture capitalists and investors

Scope of the Report:

The research report categorizes the market into the following segments and subsegments:

Immunofluorescence Assay Market, By Product;

Introduction

Reagents Stains & Dyes Media & Sera Fixatives Buffers Probes Solvents Other Reagents

Instruments Microscopes Imaging Analysis Systems

Antibodies Primary Antibodies Secondary Antibodies

Kits

Consumables and Accessories

Immunofluorescence Assay Market, By Type

Introduction

Indirect Immunofluorescence

Direct Immunofluorescence

Immunofluorescence Assay Market, By Disease

Introduction

Cancer

Infectious Diseases

Autoimmune Diseases

Cardiovascular Diseases

Other Diseases

Immunofluorescence Assay Market, By End User

Introduction

Pharmaceutical and Biotechnology Companies

Academic and Research Institutes

Hospitals and Diagnostic Centers

Contract Research Organizations

Immunofluorescence Assay Market, by Region

North America US Canada

Europe Germany France UK Italy Spain Rest of Europe

Asia Pacific Japan China India Rest of Asia Pacific

Rest of World Latin America Middle East & Africa



Available Customization

With the given market data, MarketsandMarkets offers customizations as per the company�s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (Up to 5)

Geographic Analysis

Further breakdown of the Rest of APAC market into Australia, New Zealand, and others

Further breakdown of the Rest of Europe market into Belgium, Russia, Netherlands, Switzerland, and others

Further breakdown of the Latin American market into Brazil, Mexico, and others

The global immunofluorescence assay market is projected to reach USD 2.01 Billion by 2023 from USD 1.51 Billion in 2018, at a CAGR of 5.8%. The increasing prevalence of chronic diseases, increasing R&D spending, and increasing healthcare spending are the major factors driving the growth of the market.

The report analyzes the global market by product, type, disease, end user, and region. On the basis of product, the reagents segment accounted for the largest share of the global market in 2017. The growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields, the rising prevalence of a number of diseases, growing R&D activities, and government initiatives to strengthen national research capabilities are the factors attributing for the largest share of the reagents segment.

Based on type, the global market is segmented into indirect and direct immunofluorescence. In 2017, the indirect immunofluorescence accounted for the largest share of the market. The advantages of this technique, such as its sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence is the key factor increasing the adoption of this technique.

On the basis of disease, the infectious diseases segment accounted for the largest share of the global immunofluorescence assay market in 2017. The large share of this segment is attributed to the increasing prevalence of infectious diseases across the globe and the widespread adoption of immunofluorescence techniques for the study and diagnosis of infectious diseases.

Based on end user, the pharmaceutical and biotechnology companies accounted for the largest share of the global market. Factors such as the increasing use of immunofluorescence assay in the study of various diseases in drug discovery and development processes in these companies contributes for the growth of this end user segment.

Geographically, the global market is segmented into North America, Europe, Asia Pacific, and Rest of the World. In 2017, North America accounted for the largest share of the market, followed by Europe and Asia Pacific. The rising incidence of chronic diseases, increasing R&D spending, increasing research activities, favorable government funding opportunities, and the presence of key players in this region are the major factors driving the growth of the immunofluorescence assay market in North America.

High cost of immunofluorescence instruments and implementation of excise duty by the US government are the factors restraining the growth of the global immunofluorescence assay market.

The prominent players in the global market are Thermo Fisher (US), Inova Diagnostics (US), Bio-Rad (US), Abcam (UK), PerkinELmer (US), Merck Millipore (US), Cell Signaling Technology (US), MEDIPAN GMBH (Germany), Sino Biological (China), Danaher (US), and Vector Laboratories (US).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst